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In Vitro Efficacies of Clinically Available Drugs against Growth and
Viability of an Acanthamoeba castellanii Keratitis Isolate Belonging to
the T4 Genotype
Abdul Mannan Baig, Junaid Iqbal, Naveed Ahmed Khan
Department of Biological and Biomedical Sciences, Aga Khan University, Karachi, Pakistan
The effects of clinically available drugs targeting muscarinic cholinergic, adrenergic, dopaminergic, and serotonergic receptors;
intracellular calcium levels and/or the function of calcium-dependent biochemical pathways; ion channels; and cellular pumps
were tested against a keratitis isolate of Acanthamoeba castellanii belonging to the T4 genotype. In vitro growth inhibition
(amoebistatic) assays were performed by incubating A. castellaniiwith various concentrations of drugs in the growth medium
for 48 h at 30°C. To determine amoebicidal effects, amoebae were incubated with drugs in phosphate-buffered saline for 24 h,
and viability was determined using trypan blue exclusion staining. For controls, amoebae were incubated with the solvent alone.
Of the eight drugs tested, amlodipine, prochlorperazine, and loperamide showed potent amoebicidal effects, as no viable tropho-
zoites were observed (>95% kill rate), while amiodarone, procyclidine, digoxin, and apomorphine exhibited up to 50% amoebi-
cidal effects. In contrast, haloperidol did not affect viability, but all the drugs tested inhibited A. castellanii growth. Importantly,
amlodipine, prochlorperazine, and loperamide showed compelling cysticidal effects. The cysticidal effects were irreversible, as
cysts treated with the aforementioned drugs did not reemerge as viable amoebae upon inoculation in the growthmedium. Ex-
cept for apomorphine and haloperidol, all the tested drugs blocked trophozoite differentiation into cysts in encystation assays.
Given the limited availability of effective drugs to treat amoebal infections, the clinically available drugs tested in this study rep-
resent potential agents for managing keratitis and granulomatous amoebic encephalitis caused by Acanthamoeba spp. and possi-
bly against other meningoencephalitis-causing amoebae, such as Balamuthia mandrillaris and Naegleria fowleri.
Acanthamoeba spp. are causative agents of painful blinding ker-atitis, frequently associated with contact lens wear, and gran-
ulomatous amoebic encephalitis (GAE), which almost always re-
sults in death (1–3). The approximate rate of Acanthamoeba
encephalitis-associated deaths has been suggested to be 1.57
deaths per 10,000 HIV/AIDS deaths in developed countries, while
the number of infections may be much higher in developing coun-
tries with warmer climates due to increased ubiquity, increased
outdoor activities, and/or limited availability of highly active an-
tiretroviral therapy (HAART) (4). The incidence rate of Acanth-
amoeba keratitis (AK) varies between different geographical loca-
tions. For example, in Hong Kong, an incidence rate of 0.33 per
10,000 contact lens wearers is reported, 0.05 per 10,000 in Hol-
land, 0.01 per 10,000 in the United States, 0.19 per 10,000 in Eng-
land, and 1.49 per 10,000 in Scotland (reviewed in reference 4).
However, these variations do not reflect the geographical distri-
bution of Acanthamoeba and are most likely due to extended wear
of contact lenses, lack of awareness of the potential risks associated
with wearing contact lenses, enhanced detection, and/or local
conditions that promote the growth of pathogenic amoebae only,
e.g., water hardness or salinity. Current methods for treatment of
AK include application of a mixture of drugs for prolonged peri-
ods, and even then, the outcome remains extremely poor (1–4).
For example, the treatment of AK includes an hourly topical ap-
plication of 0.02% polyhexamethylene biguanide or 0.02%
chlorhexidine digluconate, together with a diamidine (0.1% pro-
pamidine isethionate, also known as Brolene, or 0.1% hexami-
dine, also known as Desomedine), for 4 to 5 days. Subsequently,
application is reduced to every 2 hours during the day for up to a
month (5). This is followed by application 6 times a day for the
next several months to a year, and even then, the recurrence rate is
more than 10%. If bacteria are also associated or suspected with
the infection, the addition of an antibiotic, i.e., neomycin or chlor-
amphenicol, is recommended. For encephalitis, the current ther-
apeutic agents include a combination of ketoconazole, flucona-
zole, sulfadiazine, pentamidine isethionate, amphotericin B,
azithromycin, itraconazole, rifampin, voriconazole, and miltefos-
ine, which may be effective against the central nervous system
infections due to free-living amoebae (6, 7), but the mortality rate
remains high (1–3). Thus, there is an urgent need for improved
antimicrobial chemotherapy and/or alternative strategies to de-
velop therapeutic interventions. The majority of human infec-
tions due to Acanthamoeba have been associated with isolates of
the T4 genotype. For example, more than 90% of AK cases have
been linked with the genotype. Similarly, T4 has been the major
genotype associated with nonkeratitis infections, such as GAE and
cutaneous infections (1–4). Here, using growth inhibition and
viability assays, the effects of clinically available drugs targeting
various cellular receptors and biochemical pathways were tested
against an axenically grown keratitis isolate of Acanthamoeba cas-
tellanii belonging to the T4 genotype.
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MATERIALS AND METHODS
All chemicals were purchased from Sigma (Poole, Dorset, United King-
dom) unless otherwise stated. Among various drugs tested, amlodipine,
apomorphine, and loperamide were purchased from Sigma; procyclidine
was purchased from Auden McKenzie Pharma; haloperidol was pur-
chased from Searle Pharma Ltd.; amiodarone and prochlorperazine were
purchased from Sanofi-Aventis; and digoxin was purchased from Glaxo-
SmithKline (Table 1). All drugs tested are available clinically, and some
are used to treat nervous system disorders (Table 1).
Acanthamoeba cultures. A keratitis isolate of A. castellanii belonging
to the T4 genotype was grown in 10 ml of PYG medium (0.75% [wt/vol]
proteose peptone, 0.75% [wt/vol] yeast extract, and 1.5% [wt/vol] glu-
cose) in T-75 tissue culture flasks at 37°C without shaking (8). The media
were refreshed 15 to 20 h prior to experiments.A. castellanii cells adhering
to flasks represented the trophozoite form and were collected by placing
the flasks on ice for 30 min with gentle agitation and used in all experi-
ments.
Amoebistatic andamoebicidal assays.To determine the amoebistatic
activities of drugs, A. castellanii trophozoites (2 105 amoebae/ml/well)
were incubated in PYG medium with different concentrations (10 g to
500 g per ml) of drugs in 24-well plates at 30°C for 48 h. After this
incubation, the amoebae were counted using a hemocytometer. The data
are represented as the means and standard errors of at least three inde-
pendent experiments performed in duplicate. To determine the amoebi-
cidal effect of drugs on A. castellanii, amoebicidal assays were performed.
Briefly, A. castellanii trophozoites were incubated with different concen-
trations of drugs (10 g to 500 g per ml) in phosphate-buffered saline
(PBS) in 24-well plates (5 105 amoebae/ml/well). The plates were incu-
bated at 37°C for 24 h. Following this incubation, amoeba viability was
determined by adding 0.1% trypan blue and determining the number of
live (nonstained) and dead (stained) A. castellanii organisms (between
200 and 300) using a hemocytometer. The counts from A. castellanii in-
cubated with PBS alone were used as controls. Data are represented as the
means and standard errors of at least three independent experiments per-
formed in duplicate.
Encystation assays. For encystation assays, 2  106 amoebae were
incubated in PBS containing 50 mM MgCl2 and 10% glucose in 24-well
plates, without shaking, at 30°C for 72 h. After this incubation, the num-
ber of amoebae was determined using a hemocytometer, followed by ad-
dition of sodium dodecyl sulfate (SDS) (0.5% final concentration) for 10
min. The SDS-solubilized trophozoites (cysts are resistant to SDS at 0.5%
concentration, and they remain intact) and cysts were enumerated using a
hemocytometer. The data are represented as the means and standard er-
rors of at least three independent experiments performed in duplicate. To
determine the effects of drugs on amoeba differentiation, encystation as-
says were performed in the presence of various drugs. Briefly, 2  106
amoebae were incubated in PBS with various concentrations (10g to 500
g per ml) of drugs in the presence of 50 mM MgCl2 and left at room
temperature for 1 h. After this, 10% glucose was added as a trigger for
encystation in each well, and the amoebae were incubated at 30°C for 72 h.
Finally, amoeba cysts were enumerated using a hemocytometer as de-
scribed above.
Cysticidal assays. For cysticidal assays, 2 106 amoeba trophozoites
were inoculated on nonnutrient agar plates, and the plates were incubated
for up to 7 days to allow trophozoite transformation into the cyst stage.
After this incubation, each plate was flooded with 10 ml of PBS, and the
cysts were scraped off the agar surface using a rubber scraper, yielding
more than 99% cysts. The mature cysts (approximately 2  106) were
incubated in PBS with various concentrations of drug (10g to 500g per
ml) for up to 24 h. After this incubation, the cysts were centrifuged for 10
min at 1,000  g, and the supernatants were aspirated, followed by the
addition of 0.5 ml of PBS. This process was repeated 3 times to remove
extracellular drug. Finally, the cysts were resuspended in PYG medium
and inoculated in 24-well plates (0.5 ml PYG medium/well). The plates
were incubated at 30°C for 48 h, and emergence of trophozoites was
considered to indicate viable amoebae while the absence of excystation
was considered a cysticidal effect. In some experiments, plates were
incubated for up to a week to observe the emergence of viable tropho-
zoites.
RESULTS
Prochlorperazine, haloperiadol, and digoxin abolish Acanth-
amoeba growth at 25 g per ml. A. castellanii trophozoites were
incubated with various concentrations of drugs in growth me-
dium for their amoebistatic effects. In controls, A. castellanii tro-
TABLE 1 Clinically available drugs tested in this study and their known modes of action
Drug Clinical use Mode of action
Amiodarone Various types of cardiac dysrhythmias,
both ventricular and atrial
Class III antiarrhythmic agent; shows beta blocker-like and potassium channel
blocker-like actions
Binding to the nuclear thyroid receptor
Apomorphine Parkinson’s disease, erectile
dysfunction, Alzheimer’s disease
Nonselective (D) dopaminergic receptor agonist
An antagonist at 5-HT and -adrenergic receptors
Digoxin Atrial fibrillation and atrial flutter Binds to sodium/potassium-transporting ATPase alpha-1 chain to inhibit its
function at heart muscle cells and other tissues
Inhibitor of cholesterol side chain cleavage enzyme, mitochondrial
Haloperidol Schizophrenia and acute psychotic
states and delirium and
neuroleptanalgesia
Dopamine antagonist
Muscarinic receptor antagonist
Histamine antagonist
Loperamide Used against diarrhea; inhibits local
release of acetylcholine
-Opioid receptor agonist
Calmodulin binder
Prochlorperazine Nausea, vertigo, and migraine
headaches
Dopamine (D2) receptor antagonist
Muscarinic receptor antagonist
Histamine antagonist
Procyclidine Parkinsonism, akathisia, and acute
dystonia
Blocks the neurotransmitter acetylcholine in the central and peripheral
nervous system at muscarinic receptors
Amlodipine Antihypertensive and in the treatment
of angina pectoris
Calcium antagonist that inhibits the transmembrane influx of calcium ions
into vascular smooth muscle and cardiac muscle
Acts as a functional inhibitor of acid sphingomyelinase (sphingomyelin is
involved in signal transduction and apoptosis, or cell death)
Baig et al.
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phozoites were incubated in PBS (nonnutrient) and exhibited no
growth (Fig. 1), while A. castellanii incubated in PYG medium
(growth medium) exhibited8-fold increase in amoeba numbers
from the original inoculum (Fig. 1). Among various drugs tested,
prochlorperazine, haloperidol, digoxin, and amlodipine abol-
ishedA. castellanii growth. The minimum concentrations of drugs
required to significantly inhibit A. castellanii growth are shown in
Fig. 1 (P  0.01 using a paired t test with one-tail distribution).
The results revealed that concentrations of prochlorperazine,
haloperidol, and digoxin as low as 25g per ml showed more than
90% growth inhibition (Fig. 1). In contrast, the minimum con-
centration of loperamide or procyclidine required to block A. cas-
tellanii growth was 250 g per ml (Fig. 1), while 100 g per ml of
amiodarone and 50g per ml of amlodipine were needed to block
A. castellanii growth (Fig. 1).
At 500g perml, amlodipine, digoxin, loperamide, and pro-
chlorperazine showed up to 100% A. castellanii killing. To de-
termine the effects of various drugs tested on A. castellanii viabil-
ity, trophozoites were incubated with different concentrations of
drugs in PBS and cell viability was determined using trypan blue
exclusion staining. At 500g per ml, amlodipine, digoxin, lopera-
mide, and prochlorperazine produced up to 100% A. castellanii
death (Fig. 2), while amiodarone, procyclidine, and apomorphine
showed up to 50% A. castellanii death (Fig. 2). In contrast, halo-
peridol did not affect A. castellanii viability (Fig. 2).
Amiodarone, amlodipine,digoxin, and loperamideblocken-
cystation of A. castellanii. Encystation assays were performed in
the presence or absence of various drugs. At 500 g per ml, all
drugs tested except apomorphine and haloperidol exhibited more
than 90% inhibition of encystation (Fig. 3). Notably, the encysta-
tion-inhibitory effects of amlodipine, digoxin, prochloperazine,
and loperamide are secondary and are most likely due to their
potent (more than 95%) amoebicidal effects.
Amlodipine, prochlorperazine, and loperamide showed po-
tent cysticidal effects against A. castellanii cysts. Cysts were
scraped from nonnutrient agar plates and incubated in the pres-
ence or absence of various drugs for 24 h. After this incubation, the
cysts were centrifuged and reinoculated in fresh PYG medium for
up to 48 h. The results revealed that 500 g per ml of amlodipine,
prochlorperazine, and loperamide irreversibly damaged A. castel-
lanii cysts (Fig. 4). Even longer incubations did not allow re-
emergence of amoeba trophozoites. Viable A. castellanii tro-
phozoites emerged in control wells, as well as with all other
drugs tested (Fig. 4). Of note, chlorhexidine, pentamidine is-
ethionate, and ketoconazole were used, as drugs currently in
use against Acanthamoeba. Consistent with previous findings,
all compounds tested showed potent amoebicidal but limited
cysticidal effects (reference 4 and data not shown).
DISCUSSION
Keratitis and encephalitis caused by Acanthamoeba are serious
human infections. The current treatment regimen involves a mix-
ture of drugs to provide additive/synergistic effects, but the prog-
nosis remains poor (1–5). This may be due to difficulties in diag-
nosis resulting in delay in initiation of chemotherapy, poor
penetration of antimicrobial compounds across the blood brain
barrier, and perhaps the ability of amoebae to switch phenotype
into the resistant cyst form. Here, the effects of various clinically
approved compounds on growth, viability, and encystation of A.
castellanii were studied. The results demonstrated antiacantha-
moebal properties through inhibition of growth and proliferation
and by affecting the viability of the amoebae. Most of the drugs
tested in the present study are FDA approved for use against non-
communicable diseases, with known mechanisms of action on
target cells.
Of the eight drugs tested, three (amlodipine, loperamide, and
FIG 1 A. castellanii (2 105 cells) was incubated with various concentrations of drugs in PYG medium at 30°C for 48 h. After incubation, A. castellanii numbers
were monitored by hemocytometer counting. A. castellanii incubated in PBS (nonnutrient) exhibited no growth, while A. castellanii incubated in PYG medium
(growth medium) exhibited 8-fold increase in amoeba numbers from the original inoculum. All drugs tested showed significant inhibition of A. castellanii
growth at the indicated concentrations (P 0.01; paired t test; one-tail distribution). Among various drugs tested, prochlorperazine, haloperidol, and digoxin
inhibited A. castellanii growth completely at 25 g per ml. The results are representative of at least three independent experiments performed in duplicate. The
data are presented as means and standard errors.
Antiamoebic Effects of Clinically Approved Drugs
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prochlorperazine) showed more than 99% amoebicidal, as well as
cysticidal, effects. Amlodipine is a dihydropyridine calcium chan-
nel blocker used in the treatment of hypertension and angina pec-
toris (9, 10). Its distinctive pharmacokinetic characteristics are
attributed to a high degree of ionization. Following oral adminis-
tration of 5 to 10 mg, the plasma concentration rises gradually to
peak within 6 to 8 h, and its half-life is 40 to 50 h. It is metabolized
by the liver into pyridine metabolites, while 60% of the adminis-
tered dose is excreted in urine as inactive metabolites; oral toxicity
(50% lethal dose [LD50]) in mice is 37 mg per kg of body weight.
Loperamide is a widely used antidiarrheal that acts primarily
through activation of opioid receptors in the gastrointestinal tract
(9, 10). Its maximum daily oral dose is 16 mg per kg of body
weight in adults, and its half-life is 9.1 to 14.4 h, with peak plasma
levels within 5 h after oral administration. The unchanged com-
pound and its metabolite, N-demethylated loperamide, are ex-
creted through feces, while oral toxicity (LD50) in mice is 105 mg
per kg. The maximum daily oral dose for prochlorperazine is 50
FIG 2 The amoebicidal effects of various drugs were determined using trypan blue staining. Briefly, A. castellanii (5 105 amoebae) was incubated with various
drugs (500g per ml) at 37°C for 24 h. After this incubation, viability was determined by trypan blue staining, and amoebae were enumerated by hemocytometer
counting. At 500g per ml, amlodipine, loperamide, and prochlorperazine showed more than 99% A. castellanii killing. The results are representative of at least
three independent experiments performed in duplicate. The data are presented as means and standard errors.
FIG 3 Encystation assays were performed in the presence of various drugs. Briefly, 2 106 amoebae were incubated with various drugs (500 g per ml) in the
presence of 50 mM MgCl2 for 1 h. After this incubation, 10% glucose was added, and the amoebae were incubated at 30°C for 72 h. After the incubation, 0.5%
SDS was added to solubilize trophozoites (cysts are resistant to SDS), and cysts were enumerated using a hemocytometer. At 500g per ml, all drugs tested except
apomorphine and haloperidol exhibited more than 90% inhibition of A. castellanii encystation. The results are representative of at least three independent
experiments performed in duplicate. The data are presented as means and standard errors.
Baig et al.
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mg per day in adults and 12.5 mg intravenously (i.v.), and the
half-life is 8 to 9 h, with peak plasma levels within 6 h, but it may
exhibit a wide range of side effects, such as acute dystonic reac-
tions, pseudoparkinsonism, or akathisia. The N-desmethyl me-
tabolite is detected, while oral toxicity (LD50) in mice is 400 mg per
kg (10). All three agents mentioned above broadly affect intracel-
lular calcium levels and/or the function of calcium-dependent
biochemical pathways, which may explain their amoebicidal and
cysticidal effects in vitro. Acanthamoeba viability is heavily depen-
dent on its ability to crawl, approach food particles, phagocytose,
encyst and excyst, and divide to reproduce, and thus, drugs affect-
ing these functions have deleterious effects on its viability. Among
other functions, calcium effects cytoskeletal changes by stimulat-
ing myosin contractility (11), activation of actin filament severin
(12), inhibition of actin cross-linking by alpha-actinin (13), or
binding to calmodulin (14) or other low-molecular-weight calci-
um-binding proteins, including CBP (15) and calpain (16). Sev-
eral actin-associated proteins, such as actophorin (17); actobindin
(18); and 23,000-, 28,000-, 32,000-, and 38,000-Da gelation pro-
teins (19) and calcium-sensitive actin gelation protein (20, 21),
have been purified and characterized. A cDNA clone encoding an
actin-bundling protein, AhABP, was recently isolated from Acan-
thamoeba healyi, a causative agent of granulomatous amoebic en-
cephalitis (22). Additionally, several Acanthamoeba extracellular
proteases act in a calcium-dependent manner (23, 24).
At a high concentration, loperamide affected A. castellanii via-
bility. Loperamide is an opiate that reduces calcium influx across
cell membranes and/or decreases cellular availability of calcium
(25) and is used in the treatment of diarrhea (26). At higher con-
centrations, loperamide blocks calmodulin activity, calcium
channels, N-methyl-D-aspartate receptor channels, and mai-
totoxin-elicited calcium influx. At micromolar concentrations, it
has a remarkable stimulatory effect on the capacitative calcium
influx that is triggered in many cells by depletion of the inositol-
triphosphate-sensitive stores of calcium in the endoplasmic retic-
ulum (27). In our assays, loperamide showed potent amoebicidal
and cysticidal effects at high concentrations, probably by affecting
regulatory intermediates and/or some yet-unidentified cardinal
biochemical pathways in A. castellanii.
An indirect role of calcium in inhibition of transformation due
to a calcium-regulatory protein and its control of cyclic nucleotide
levels in the cell has been proposed based on inhibition by triflu-
operazine, a calmodulin antagonist (28). In our study, prochlor-
parazine, a drug of the same class as trifluoperazine, produced
potent amoebicidal and cysticidal effects. Haloperidol and pro-
chlorperazine act primarily as dopamine receptor blockers and
have been used as antipsychotic drugs. It was interesting that pro-
chlorperazine showed potent amoebicidal, as well as cysticidal,
effects, while haloperidol was effective against trophozoites but
not cysts. This is consistent with previous studies, which showed
that chlorpromazine is effective against trophozoites and cysts of
A. castellanii (29). Notably, haloperidol has bioavailabilities of
100% via the i.v. route and 60 to 65% by the oral route and has
rapid onset of action, within a few hours. The concentration of
haloperidol in brain tissue is about 20-fold higher than blood
levels. It is slowly eliminated from the brain tissue. The elimina-
tion half-life is about 3 weeks, and excretion is via biliary and renal
routes. Previous studies have shown that a combination of chlor-
promazine and rokitamycin exhibited synergistic amoebistatic,
amoebicidal, and cysticidal activities against A. castellanii, sug-
gesting their usefulness as chemotherapeutic agents against
Acanthamoeba infections (29). The precise mode of action of pro-
FIG4 Representative effects of various drugs againstA. castellanii cysts.A. castellanii cysts were scraped from nonnutrient agar plates and incubated with various
drugs (500 g per ml) for 24 h. After this incubation, the cysts were washed three times with PBS and reinoculated in fresh PYG medium at 30°C for up to 48 h.
When treated with 500 g per ml of amlodipine, prochlorperazine, and loperamide, A. castellanii cysts did not reemerge as viable A. castellanii trophozoites.
Viable A. castellanii trophozoites emerged in control wells, as well as with all other drugs. The results are representative of three independent experiments.
Antiamoebic Effects of Clinically Approved Drugs
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chlorparazine againstAcanthamoeba is unclear, but it may involve
inhibition of amoeba calcium-regulatory proteins or lipophilic
action on the amoeba plasma membrane (10, 29). Prochlorpera-
zine is thought to exert its antipsychotic effects by blocking dopa-
mine receptors but also has moderate anticholinergic and alpha-
adrenergic receptor-blocking activity compared to haloperidol,
which is a weak anticholinergic (muscarinic) M1 (silent antago-
nist) at 10,000 nM (30). Consistent with our findings and the
differential affinities of prochlorperazine and haloperidol for cho-
linergic receptors in particular, it is tempting to speculate about
the presence of a cholinergic receptor (M1) subtype on A. castel-
lanii, and studies are in progress to address this issue.
Another anticholinergic agent included in our study was pro-
cyclidine, which is widely used as an antiparkinsonian agent be-
cause of its anticholinergic action (31). Procyclidine primarily an-
tagonizes muscarinic receptors M1, M2, and M4, of which M1 and
M4 are diffusely distributed throughout the brain. Procyclidine
showed substantial effects as an amoebicidal drug in our assays.
Subcutaneous doses of 300 mg per kg are not toxic, and oral ab-
sorption of procyclidine is 100%. The plasma half-life is 12.6 h,
while the intravenous LD50 in mice is about 60 mg per kg of
body weight (10). Among other drugs tested, apomorphine is a
nonselective dopamine agonist that activates dopamine receptors,
D1- and D2-receptors, with preference for the latter subtype (32).
Apomorphine also possesses agonistic affinity for receptors like
5-HT1A, 5-HT2A, 5-HT2B, and 5-HT2C (32). As prochlorperazine,
chlorpromazine, and haloperidol are D1 and D2 receptor antag-
onists, it is logical to conclude that either they act on A. castellanii
via receptors other than the D-receptor subtype or apomorphine
exhibited its effects via 5HT or some other receptor subtype (10),
and this will be the subject of future studies. Of note, subcutane-
ous and/or intravenous administration exhibits 100% bioavail-
ability, with a half-life of 40 min. Potential routes of metabolism in
humans include sulfation, N-demethylation, glucuronidation,
and oxidation. The maximum concentration in cerebrospinal
fluid (CSF) occurs 10 to 20 min after administration. Digoxin is a
potent inhibitor of the active transport of sodium and potassium
across cell membranes. This biological effect is accomplished by
binding to Na and K-ATPase, resulting in the inhibition of the
cellular ion pump in a reversible manner (33). Although the
mechanism of action as an antiamoeba agent remains unidenti-
fied, a combination of lytic and apoptotic signaling induction may
contribute to its amoebicidal effects observed in the present study.
Digoxin crosses both the blood brain barrier and the placenta.
Following intravenous administration to healthy volunteers, 50%
to 70% of the digoxin dose is excreted unchanged in the urine, and
only a small percentage (16%) of the given dose is metabolized,
with a half-life of about 36 h. The end metabolites include 3--
digoxigenin, 3-keto-digoxigenin, and their glucuronide and sul-
fate conjugates (10). Amiodarone effects may be mediated by per-
turbation of the lipid environment of the ion channels.
Amiodarone resembles thyroxin (thyroid hormone) chemically,
and its binding to the nuclear thyroid receptor might contribute to
its pharmacological properties. It has a bioavailability of approx-
imately 50%, with the maximum plasma concentration attained
within 3 to 7 h, and a half-life of 58 days. Amiodarone is metabo-
lized to desethylamiodarone by the cytochrome P450 (CYP450)
enzyme group in the liver, and excretion is primarily via hepatic
and biliary routes. In conclusion, for the first time we have shown
that a diverse group of drugs affecting the cellular availability of
calcium, sodium, and potassium ions through surface and
metabotropic receptors exert a possible electrophysiological effect
on A. castellanii, inhibiting growth, viability, and encystation. Fu-
ture studies will dissect the molecular mechanisms to validate the
mode of action of these drugs and/or identify novel biochemical
pathways and receptors.
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